158 related articles for article (PubMed ID: 16861316)
1. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases.
Linton KM; Taylor MB; Radford JA
Br J Radiol; 2006 Aug; 79(944):e40-4. PubMed ID: 16861316
[TBL] [Abstract][Full Text] [Related]
2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
3. Cystic changes in intraabdominal extrahepatic metastases from gastrointestinal stromal tumors treated with imatinib.
Kim HC; Lee JM; Choi SH; Han H; Kim SS; Lee SH; Han JK; Choi BI
Korean J Radiol; 2004; 5(3):157-63. PubMed ID: 15467412
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
De Giorgi U; Aliberti C; Benea G; Conti M; Marangolo M
Clin Cancer Res; 2005 Sep; 11(17):6171-6. PubMed ID: 16144917
[TBL] [Abstract][Full Text] [Related]
5. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
Mabille M; Vanel D; Albiter M; Le Cesne A; Bonvalot S; Le Péchoux C; Terrier P; Shapeero LG; Dromain C
Eur J Radiol; 2009 Feb; 69(2):204-8. PubMed ID: 19046841
[TBL] [Abstract][Full Text] [Related]
6. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.
Vanel D; Albiter M; Shapeero L; Le Cesne A; Bonvalot S; Le Pechoux C; Terrier P; Petrow P; Caillet H; Dromain C
Eur J Radiol; 2005 Apr; 54(1):118-23. PubMed ID: 15797301
[TBL] [Abstract][Full Text] [Related]
7. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
[TBL] [Abstract][Full Text] [Related]
8. [A case of recurrent gastrointestinal stromal tumor progressing after interruption of long-term imatinib therapy].
Nakatsuka R; Takahashi T; Miyazaki Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2478-80. PubMed ID: 25731563
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
10. [A case of liver and bone metastasis from gastrointestinal stromal tumor treated using imatinib].
Murakami M; Ebisui C; Okada K; Okamura S; Murata K; Nakagomi N; Tamai M; Kinuta M
Gan To Kagaku Ryoho; 2014 Jan; 41(1):99-101. PubMed ID: 24423961
[TBL] [Abstract][Full Text] [Related]
11. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
12. Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
Ulusan S; Koç Z; Kayaselçuk F
Turk J Gastroenterol; 2008 Jun; 19(2):129-32. PubMed ID: 19110671
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
[TBL] [Abstract][Full Text] [Related]
15. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F
Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of recurrent GIST successfully treated with imatinib mesylate at 100mg/day].
Hanada N; Kawata K; Okamura S; Tomiyama N; Hori K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):803-5. PubMed ID: 23863663
[TBL] [Abstract][Full Text] [Related]
17. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
18. [A resected case of postoperative liver metastasis of a gastrointestinal stromal tumor showing complete response after imatinib treatment].
Yamamura M; Hirai T; Higashida M; Kubota H; Murakami H; Kawabe Y; Ikeda M; Hirabayashi Y; Okawaki M; Hironaka K; Oka Y; Okumura H; Akiyama T; Matsumoto H; Urakami A; Yamashita K; Yamaguchi Y; Tsunoda T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1945-9. PubMed ID: 19011349
[TBL] [Abstract][Full Text] [Related]
19. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
[TBL] [Abstract][Full Text] [Related]
20. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
